Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719954 | 0.87 | ALDH1A1 (0.38) | ALDH1A1GAAMAOBKMT2AMEN1 | |
| SCHEMBL30954811 | 0.87 | MMP1 (0.39) | ALDH1A1GAAMAOBKMT2AMEN1 | |
| SCHEMBL1503250 | 0.87 | MMP1 (0.39) | ALDH1A1GAAMAOBKMT2AMEN1 | |
| SCHEMBL15746710 | 0.86 | NR4A2 (0.45) | ALDH1A1GAAMAOBMAPTNPC1 | |
| SCHEMBL1503300 | 0.86 | ADAMTS4 (0.37) | ALDH1A1GAAMAOBKMT2AMAPT | |
| SCHEMBL1503217 | 0.85 | ALDH1A1 (0.43) | ALDH1A1GAAMAOBKMT2AMAPT | |
| SCHEMBL22719956 | 0.85 | ALDH1A1 (0.38) | ALDH1A1GAAMAOBKMT2AMAPT | |
| SCHEMBL22738288 | 0.85 | GABRA5 (0.42) | ALDH1A1GAAKMT2AMAPTNPC1 | |
| SCHEMBL2220322 | 0.85 | ALDH1A1 (0.40) | ALDH1A1MAOBKMT2AMAPTNPC1 | |
| SCHEMBL22738236 | 0.83 | EGLN1 (0.39) | ALDH1A1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | claimed |
| CN-102112447-B | HIV integrase inhibitors from pyridoxine | AMBRILIA BIOPHARMA INC | 2013-06-26 | — | — | CN | claimed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | claimed |
| CN-102112447-A | HIV integrase inhibitors from pyridoxine | AMBRILIA BIOPHARMA INC | 2011-06-29 | — | — | CN | claimed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | claimed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | claimed |
| EP-3687538-B1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INST (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| WO-2020237374-A1 | PICOLINIC ACID DERIVATIVES AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH ELEVATED CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2020-12-03 | — | — | WO | disclosed |
| EP-3687538-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montreal Heart Institute (CA) | 2020-08-05 | — | — | EP | disclosed |
| CN-102112447-B | HIV integrase inhibitors from pyridoxine | AMBRILIA BIOPHARMA INC | 2013-06-26 | — | — | CN | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| CN-102112447-A | HIV integrase inhibitors from pyridoxine | AMBRILIA BIOPHARMA INC | 2011-06-29 | — | — | CN | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | ALDH1A1 568/4885GAA 776/4885MAOB 1830/4885 |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | ALDH1A1 334/4885GAA 1848/4885MAOB 40/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | ALDH1A1 568/4885GAA 776/4885MAOB 1830/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | ALDH1A1 568/4885GAA 776/4885MAOB 1830/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | ALDH1A1 568/4885GAA 776/4885MAOB 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.